...
机译:EPO衍生物ARA290通过靶向NF-Kappa B途径衰减大鼠早期肾同种异体移植物损伤
Zhengzhou Univ Peoples Hosp Blood Purificat Ctr Zhengzhou Henan Peoples R China;
Zhengzhou Univ Peoples Hosp Blood Purificat Ctr Zhengzhou Henan Peoples R China;
Zhengzhou Univ Peoples Hosp Blood Purificat Ctr Zhengzhou Henan Peoples R China;
Zhengzhou Univ Peoples Hosp Blood Purificat Ctr Zhengzhou Henan Peoples R China;
Zhengzhou Univ Peoples Hosp Blood Purificat Ctr Zhengzhou Henan Peoples R China;
Zhengzhou Univ Peoples Hosp Blood Purificat Ctr Zhengzhou Henan Peoples R China;
Zhengzhou Univ Peoples Hosp Blood Purificat Ctr Zhengzhou Henan Peoples R China;
机译:EPO衍生物ARA290通过靶向NF-Kappa B途径衰减大鼠早期肾同种异体移植物损伤
机译:非促红细胞生成素EPO衍生物ARA290可减轻肾缺血/再灌注损伤
机译:非促红细胞生成素EPO衍生物ARA290可减轻肾缺血/再灌注损伤
机译:镧通过raw264.7细胞中的NF-κB通路抑制靶基因表达
机译:使用venzoporphyrin衍生的单酸环A(BPD)verteporfin的光动力疗法(PDT)预防皮肤异体移植排斥
机译:非促红细胞生成素EPO衍生物ARA290可减轻肾缺血/再灌注损伤
机译:非促红细胞生成素EPO衍生物ARA290可减轻肾缺血/再灌注损伤